The information contained in these releases was current on the date the releases were issued and will become outdated over time. Lilly does not assume any responsibility for updating information in these releases.
Releases
 |
Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta(R) to a Broader Pain Population
Aug 19, 2010
|
11.6 KB |
|
| |
BETHESDA, Md., Aug 19, 2010 /PRNewswire via COMTEX News Network/ -- The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted today 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta(R) (duloxetine HCl) to a broader pain population that will be further defined...
|
|
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Aug 17, 2010
|
12.8 KB |
|
| |
INDIANAPOLIS, Aug 17, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression an...
|
|
The American Diabetes Association and Eli Lilly and Company Encourage African-Americans to Face the Music about Diabetes Management
Aug 5, 2010
|
13.0 KB |
|
| |
ATLANTA, Aug 05, 2010 /PRNewswire via COMTEX News Network/ -- The 12th annual Victory Over Diabetes event, hosted by the American Diabetes Association (the Association), will take place in Atlanta on August 7, featuring Eli Lilly and Company's Fearless African-Americans Connected and Empowered (F.A.C.E.) Diabetes initiative and campaign spokesperso...
|
|
Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
Jun 28, 2010
|
13.2 KB |
|
| |
INDIANAPOLIS and PARSIPPANY, N.J., June 28, 2010 /PRNewswire via COMTEX News Network/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix(R) (clopidogrel),...
|
|
Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
Jun 26, 2010
|
17.5 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced final results from a retrospective study including more than 260,000 patients that showed the risk of acute pancreatitis among initiators of BYETTA(R) (exenatide) injection was not in...
|
|
Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R)
Jun 26, 2010
|
17.4 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA(R) (exenatide) injection added to Lantus(R) (insulin glargine), which showed patients with ty...
|
|
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
Jun 26, 2010
|
17.8 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with either BYETTA(R) (exenatide) injection or Lantus(R) (insulin glargine) on overall beta-cell function. (Beta cells...
|
|
BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010
Jun 26, 2010
|
18.6 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results of an analysis of pooled safety data from three completed randomized controlled trials that showed the investigational product BYDUREON(TM) (exe...
|
|
Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes
Jun 22, 2010
|
12.0 KB |
|
| |
INDIANAPOLIS and BENTONVILLE, Ark., June 22, 2010 /PRNewswire via COMTEX News Network/ -- Walmart (NYSE: WMT) and Eli Lilly and Company (NYSE: LLY) announced today they're teaming up to provide an affordable insulin option for people with diabetes.
Beginning in mid-September, Lilly's Humulin(R) brand of insulin will be available in Walmart pharmac...
|
|
Kowa Pharmaceuticals America and Lilly Announce U.S. Availability of LIVALO
Jun 21, 2010
|
14.8 KB |
|
| |
MONTGOMERY, Ala. and INDIANAPOLIS, June 21, 2010 /PRNewswire via COMTEX News Network/ -- Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that LIVALO(R) (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug A...
|
|
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
Jun 15, 2010
|
17.7 KB |
|
| |
SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., June 15, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON(TM) (exenatide ex...
|
|
F.A.C.E. Diabetes Initiative Launches New Webisode Series
Jun 4, 2010
|
10.3 KB |
|
| |
INDIANAPOLIS, June 4, 2010 /PRNewswire via COMTEX News Network/ -- A free Webisode series will kick off this June to offer suggestions to help African-Americans diagnosed with type 2 diabetes better manage the disease on FACE-Diabetes.com as part of the Fearless African-Americans Connected and Empowered (F.A.C.E.) Diabetes initiative. The F.A.C.E. ...
|
|
Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
May 20, 2010
|
11.7 KB |
|
| |
INDIANAPOLIS, May 20, 2010 /PRNewswire via COMTEX News Network/ -- Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer.(1) Study results will be presented during the 46th Annual Meeting of the American Society of...
|
|
Two Studies Evaluated Full-Dose Chemotherapy Regimen and Concurrent Radiation in Treatment of Lung Cancer
May 20, 2010
|
14.4 KB |
|
| |
INDIANAPOLIS, May 20, 2010 /PRNewswire via COMTEX News Network/ -- Results of two Phase II trials evaluating ALIMTA(R) (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC) will be presented by Eli Lilly and Company at the 46th Annual Meeting of the...
|
|
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
May 17, 2010
|
22.5 KB |
|
| |
INDIANAPOLIS, May 17, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company will unveil data from 57 studies at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 4 - 8, 2010, during which the company will present the latest research results on ALIMTA®...
|
|
New Data From Lilly Oncology Pipeline To Be Presented at ASCO 2010
May 12, 2010
|
9.4 KB |
|
| |
INDIANAPOLIS, May 12, 2010 /PRNewswire via COMTEX News Network/ -- Data from several Lilly Oncology compounds in development - a total of 13 studies - will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 4 - 8, 2010. Lilly Oncology's pipeline is one of the largest in t...
|
|
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
May 6, 2010
|
16.3 KB |
|
| |
SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., May 6, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON(TM) (exenatide for extended-release injectable s...
|
|
Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON(TM)
Apr 22, 2010
|
15.3 KB |
|
| |
SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., April 22, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug A...
|
|
ALIMTA(R) Recommended by Special Health Authority in United Kingdom as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Apr 1, 2010
|
16.5 KB |
|
| |
INDIANAPOLIS, April 1, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) announced today that its chemotherapy ALIMTA(R) (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).
Specifically, NICE's Final Appra...
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
Mar 15, 2010
|
15.6 KB |
|
| |
PARSIPPANY, N.J. and INDIANAPOLIS, March 15, 2010 /PRNewswire via COMTEX News Network/ -- A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix(R) (clopidogrel) plus ...
|
|
|
